摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-2-(4-chlorobenzoyl)cyclohexane-1-carboxylic acid | 52240-18-3

中文名称
——
中文别名
——
英文名称
cis-2-(4-chlorobenzoyl)cyclohexane-1-carboxylic acid
英文别名
cis-2-p-chlorobenzoyl-1-cyclohexanecarboxylic acid;cis-(2-p-Chlorbenzoyl)-cyclohexan-1-carbonsaeure;(1R,2S)-2-(4-chlorobenzoyl)cyclohexanecarboxylic acid;(1S,2R)-2-(4-chlorobenzoyl)cyclohexane-1-carboxylic acid
cis-2-(4-chlorobenzoyl)cyclohexane-1-carboxylic acid化学式
CAS
52240-18-3;52240-19-4
化学式
C14H15ClO3
mdl
——
分子量
266.724
InChiKey
LFHRQJKEWRETIE-NEPJUHHUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    147-151°C
  • 密度:
    1.2034 (estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:5bd724a73333181fc78141262d8dba87
查看

反应信息

点击查看最新优质反应信息

文献信息

  • En Route to Diastereopure Polycyclic γ‐Lactones by Iridium‐Catalyzed Hydride Transfer†
    作者:Yang Chen、Jingyu Zhang、Yecheng Wang、Hongguang Du、Jiaxi Xu、Zhanhui Yang
    DOI:10.1002/cjoc.202400265
    日期:2024.12
    catalyst efficiency (S/C = up to 5000). Mechanistic studies suggest that the iridium hydride formation might be the rate-determining step, and that the hydride transfer step be the diastereo-determining step. The large steric hindrance of the iridium hydride species and intramolecular hydrogen bonding are critically key to the diastereocontrol of the hydride transfer process. From the perspectives of configurational
    还原性内酯化策略提供了对非对映富集多环 γ-内酯的有效访问。然而,开发一种具有出色非对映控制平的高效且多功能的方案仍然是一项艰巨的挑战。在此,我们通过催化的氢化物转移策略,提供了一种高度非对映选择性和高效的非对映纯双环和多环 γ-内酯途径。该方法具有高平的非对映控制、广泛的底物范围和高催化剂效率 (S/C = 高达 5000) 的特点。机理研究表明,氢化的形成可能是速率决定步骤,而氢化物转移步骤是非对映决定步骤。氢化物质的巨大空间位阻和分子内氢键是氢化物转移过程的非对映控制的关键。从构型分析和 Duniz 攻角的角度来看,非对映控制的性质得到了很好的合理化。还提出了一个基于面部选择性分析的更通用的经验规则,用于解释和预测立体化学
  • Regioselective Synthesis of 3-endo-Hydroxymethyl-5-exo-phenylbicyclo[2.2.1]heptan-2-endo-amine and its Transformation into Saturated or Partially Saturated Di-endo-fused Heterocycles.
    作者:Géza Stájer、Miklós Virág、Angela E. Szabó、Gábor Bernáth、Pál Sohár、Reijo Sillanpää、Muhammed Nour Homsi、Frank K. H. Kuske、Monika Haugg、Nathalie Trabesinger-Rüf、Elmar G. Weinhold
    DOI:10.3891/acta.chem.scand.50-0922
    日期:——
    AlCl3-catalysed addition of benzene to di-endo-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid (1) and subsequent treatment with acetic anhydride yields 5-exo-phenylbicyclo[2.2.1]heptane-2,3-di-endo-carboxylic anhydride (2). 3-endo-Hydroxymethyl-5-exo-phenylbicyclo[2.2.1]heptane-2-endo-amine (4) was prepared by LAH reduction of the beta-amino acid 3 obtained by Hofmann degradation of the carboxy amide prepared from 2. Reaction of 4 with ethyl chloroformate or with CS2-NaOH-Pb2+ furnished the methylene-bridged hexahydro-3,1-benzoxazin-2(1H)-one (5) or -benzoxazine-2(1H)-thione (6). With ethyl chloroacetate or 2-chloropropionate, 4 gave the tricyclic oxazepinones 7 and 8. The norbornane 1,3-amino alcohol 4 was transformed with phenyl isothiocyanate into the phenylimino-1,3-oxazine 9 and -thiazine 10. The cyclizations of 4 with 2-(p-methylbenzoyl)benzoic acid or cis-2-p-chlorobenzoyl-1-cyclohexanecarboxylic acid led to the methylene-bridged isoindolo[2,1-a][3,1]benzoxazines 11 and 12. With p-chlorobenzimidate, the di-endo-5,8-methano-4H-3,1-benzoxazine 13 was obtained, which was converted with dichloroacetic acid-triethylamine into the isomeric azetidinones 14 and 15, or with benzonitrile oxide to the methano-1,2,4-oxadiazolo[4,5-a][3,1]benzoxazine (16). The stereostructures of the new compounds were elucidated by NMR spectroscopy and for 13 also by X-ray diffractometry.
  • [EN] MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS<br/>[FR] COMPOSÉS À BASE DE PIPÉRAZINE SPÉCIFIQUES DU RÉCEPTEUR DE LA MÉLANOCORTINE
    申请人:PALATIN TECHNOLOGIES INC
    公开号:WO2008090357A2
    公开(公告)日:2008-07-31
    [EN] Melanocortin receptor-specific piperazine compounds, of the formula (I) wherein the variables are as defined in the specification, and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
    [FR] L'invention concerne des composés à base de pipérazine spécifiques du récepteur de la mélanocortine, représentés par la formule (I) dans laquelle les variables sont telles que définies dans la description, et des sels pharmaceutiquement acceptables de ceux-ci. Les composés décrits ici se lient à un ou plusieurs récepteur(s) de la mélanocortine et peuvent être un agoniste, un agoniste partiel, un antagoniste, un agoniste inverse ou un antagoniste d'un agoniste inverse pour un ou plusieurs récepteur(s) de la mélanocortine, et peuvent être utilisés pour le traitement d'un ou plusieurs état(s) pathologique(s) ou trouble(s) lié(s) au récepteur de la mélanocortine, incluant de manière spécifique le traitement de l'obésité et d'états pathologiques liés.
查看更多